Docoh
Loading...
Sign up Log in

SNGX Soligenix

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare disease. It operates through Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses in the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions solutions comprises active development programs for RiVax, ricin toxin vaccine candidate and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Company profile

Ticker
SNGX, SNGXW
Exchange
NASDAQ
Website
www.soligenix.com/
CEO
Christopher Schaber
Employees
Incorporated
Delaware
Location
New Jersey
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
Pharmaceutical Preparations
Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...
Former names
DOR BIOPHARMA INC, ENDOREX CORP, IMMUNOTHERAPEUTICS INC
SEC CIK
0000812796
Corporate docs
IRS number
411505029

SNGX stock data

(
)

News

Pro users get this 30m faster
Soligenix To Receive $865,000 In Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
9 Mar 21
PRINCETON, N.J., March 9, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare
The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company
4 Mar 21
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs March 3)
12 Health Care Stocks Moving In Thursday's Pre-Market Session
4 Mar 21
Soligenix Shares Rally On Positive Preclinical Data For COVID-19 Vaccine Candidate
4 Mar 21
Soligenix Highlights Publication Of Pre-Clinical Studies For The CiVax COVID-19 Vaccine Program
4 Mar 21

Press releases

Pro users get this 30m faster
Soligenix Receives Conditional FDA Acceptance of Proposed Brand Name HyBryte™ for SGX301 in CTCL
7 Apr 21
PRINCETON, N.J., April 7, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Soligenix Announces Recent Accomplishments And Year-End 2020 Financial Results
30 Mar 21
PRINCETON, N.J., March 30, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Soligenix to Receive $865,000 in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
9 Mar 21
PRINCETON, N.J., March 9, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases
Thinking about buying stock in Super League Gaming, Soligenix, Vascular Biogenics, BioLineRx, or electroCore?
4 Mar 21
Soligenix Announces Positive Progress in the Pre-clinical Development of its COVID-19 Vaccine
4 Mar 21

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

29 Mar 21
11 Apr 21
31 Dec 21

Financial summary

Financial statements Chart SNGX financial data
Quarter (USD)
 Dec 20 Sep 20 Jun 20 Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Soligenix earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 18.68M 18.68M 18.68M 18.68M 18.68M 18.68M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.83M 1.55M 1.37M 954.54K
Cash used (since last report) n/a n/a 6.17M 5.22M 4.64M 3.22M
Cash remaining n/a n/a 12.51M 13.45M 14.04M 15.46M
Runway (months of cash) n/a n/a 6.8 8.7 10.2 16.2

Beta Read what these cash burn values mean

Recent insider trades

SNGX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
4 Jan 21 Christopher J Schaber Option Common Stock Grant Aquire A No No 1.28 60,000 76.8K 60,000
10 Dec 20 Oreola Donini Option Common Stock Grant Aquire A No No 2.34 70,000 163.8K 70,000
10 Dec 20 Christopher J Schaber Option Common Stock Grant Aquire A No No 2.34 60,000 140.4K 60,000
10 Dec 20 Richard Straube Option Common Stock Grant Aquire A No No 2.34 40,000 93.6K 40,000
10 Dec 20 Jonathan L. Guarino Stock Option COMMON STOCK Grant Aquire A No No 2.34 40,000 93.6K 40,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

SNGX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

9.5% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 35 29 +20.7%
Opened positions 11 2 +450.0%
Closed positions 5 6 -16.7%
Increased positions 6 14 -57.1%
Reduced positions 4 4 –
13F shares
 Current Prev Q Change
Total value 3.84M 4.99M -23.1%
Total shares 3M 2.8M +7.1%
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
Vanguard 909.16K $1.16M +4.4%
Knoll Capital Management 787.83K $1.01M 0.0%
First Wilshire Securities Management 350K $448K +40.0%
Geode Capital Management 128.4K $164K 0.0%
California Public Employees Retirement System 126.17K $161K NEW
Gsa Capital Partners 118.69K $152K -12.6%
BLK Blackrock 95.52K $122K +22.8%
Plante Moran Financial Advisors 71.66K $92K 0.0%
NTRS Northern Trust 48.47K $62K 0.0%
VIRT Virtu Financial 44.1K $56K -1.7%
Largest transactions
 Shares Bought/sold Change
California Public Employees Retirement System 126.17K +126.17K NEW
First Wilshire Securities Management 350K +100K +40.0%
FNY Investment Advisers 0 -89.5K EXIT
Squarepoint Ops 0 -71.83K EXIT
ARGI Investment Services 40.88K +40.88K NEW
Occudo Quantitative Strategies 39.19K +39.19K NEW
Vanguard 909.16K +37.97K +4.4%
Two Sigma Securities 30.9K +30.9K NEW
BK Bank Of New York Mellon 28.47K +28.47K NEW
Wedbush Securities 0 -25.2K EXIT
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Abeona Therapeutics • Emergent Biosolutions
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accommodate, accrual, add, admitted, advisory, affirmative, aim, alia, allege, alleged, annum, answered, apparent, apprising, arbitration, attestation, automation, Baltimore, Bank, BDS, biased, biorxiv, borrow, borrowed, borrowing, Boston, BSX, BTG, Burkholderia, carryover, case, cellular, Chase, choose, CiVaxTM, cleaning, companion, compendia, County, CoVaccine, Daavlin, dataset, deeper, deeply, default, deviation, distancing, downstream, drawn, EBS, EMOB, emulsified, energy, enriched, EPDG, EVD, exhausted, faulty, flow, flu, forgiven, fresh, Gaithersburg, GP, grow, House, HT, humoral, HyBiopharma, Hypericum, impede, imperative, incentivize, inter, intercepted, invoice, invoiced, IRS, Japanese, JPMorgan, judgement, Kura, lender, lien, loan, mandated, manipulation, manuscript, mask, mediated, Medison, Mercer, merchantability, methodology, monthly, moving, mucobuccal, NB, necessitate, notification, pandemic, paper, patch, Paycheck, payroll, penetrating, penetration, plaque, pledged, Pontifax, potency, PPP, prepayment, preprint, prototype, quickly, reading, remotely, renegotiate, repay, repayment, repurchasing, restructuring, revealed, sanitation, Simphotek, Singapore, social, SOM, sought, Spike, stored, strong, subset, substitute, subtopic, Sudan, talent, top, tranche, trend, turnover, uneven, unjustly, unpaid, unsecured, upstream, usage, venture, vi, vigorously, vii, viii, warranty, workplace, Zaire
Removed: Amir, assigned, attainment, attribute, Ave, Brownlie, Carol, clarification, collection, dispositive, Ecker, Extensivein, FluorescentLightActivatedSyntheticHypericin, fourth, Frankenfield, guidance, inInternal, Intrexon, joined, Karen, Krumeich, Lancaster, legally, lesser, Lincoln, Managing, Master, modulatingINNATE, offered, ofHypericum, OrbeShield, owner, PA, Park, participated, predominantly, reserved, RiVax®and, RiVax®bulk, RiVax®testing, RiVax®under, ThermoVax®development, Wayne, Zolina®and
From filing 10-K 2020 FY

Financial reports

View all
10-K
2020 FY
Annual report
29 Mar 21
10-Q
2020 Q3
Quarterly report
12 Nov 20
10-Q
2020 Q2
Quarterly report
14 Aug 20
10-Q
2020 Q1
Quarterly report
15 May 20
10-K
2019 FY
Annual report
30 Mar 20
10-Q
2019 Q3
Quarterly report
12 Nov 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
10-Q
2019 Q1
Quarterly report
14 May 19
10-K
2018 FY
Annual report
26 Mar 19
10-Q
2018 Q3
Quarterly report
9 Nov 18

Current reports

View all
8-K
Regulation FD Disclosure
26 Jan 21
8-K
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
22 Dec 20
8-K
Soligenix Announces $20 Million Strategic Convertible Debt Financing Agreement with Pontifax Medison Debt Financing
16 Dec 20
8-K/A
Amendments to Articles of Incorporation or Bylaws
3 Dec 20
8-K
Submission of Matters to a Vote of Security Holders
25 Nov 20
8-K
Amendments to Articles of Incorporation or Bylaws
18 Sep 20
8-K
Advantages of the CiVax™ Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
10 Sep 20
8-K
Entry into a Material Definitive Agreement
28 Aug 20
8-K
Soligenix Issues Corporate Update – Highlights Important Catalysts for Second Half of 2020
20 Jul 20
8-K
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
30 Apr 20

Registration and prospectus

View all
S-3
Shelf registration
15 Jan 21
424B5
Prospectus supplement for primary offering
28 Aug 20
S-3/A
Shelf registration (amended)
14 Aug 20
S-3/A
Shelf registration (amended)
31 Jul 20
S-3
Shelf registration
17 Jul 20
424B5
Prospectus supplement for primary offering
10 Apr 20
424B5
Prospectus supplement for primary offering
20 Mar 20
424B5
Prospectus supplement for primary offering
3 Oct 18
424B4
Prospectus supplement with pricing info
28 Jun 18
S-1/A
IPO registration (amended)
20 Jun 18

Proxies

View all
DEFA14A
Additional proxy soliciting materials
25 Nov 20
DEF 14A
Definitive proxy
6 Nov 20
PRE 14A
Preliminary proxy
23 Oct 20
DEFA14A
Additional proxy soliciting materials
13 Aug 20
DEFA14A
Additional proxy soliciting materials
7 Aug 20
DEF 14A
Definitive proxy
7 Aug 20
PRE 14A
Preliminary proxy
24 Jul 20
DEFA14A
Additional proxy soliciting materials
26 Jul 19
DEF 14A
Definitive proxy
26 Jul 19
DEFR14A
Revised proxy
17 Aug 18

Other

View all
EFFECT
Notice of effectiveness
1 Feb 21
CORRESP
Correspondence with SEC
26 Jan 21
UPLOAD
Letter from SEC
21 Jan 21
EFFECT
Notice of effectiveness
31 Aug 20
CORRESP
Correspondence with SEC
25 Aug 20
CORRESP
Correspondence with SEC
30 Jul 20
UPLOAD
Letter from SEC
23 Jul 20
EFFECT
Notice of effectiveness
28 Jun 18
EFFECT
Notice of effectiveness
29 Nov 17
CORRESP
Correspondence with SEC
27 Nov 17

Ownership

View all
4
SOLIGENIX / CHRISTOPHER J SCHABER ownership change
4 Jan 21
4
SOLIGENIX / Jonathan L. Guarino ownership change
11 Dec 20
4
SOLIGENIX / Richard Straube ownership change
11 Dec 20
4
SOLIGENIX / CHRISTOPHER J SCHABER ownership change
11 Dec 20
4
SOLIGENIX / Oreola Donini ownership change
11 Dec 20
4
SOLIGENIX / JEROME B ZELDIS ownership change
18 Sep 20
4
SOLIGENIX / ANTHONY GREGG LAPOINTE ownership change
18 Sep 20
4
SOLIGENIX / ROBERT J. RUBIN ownership change
18 Sep 20
4
SOLIGENIX / Diane L. Parks ownership change
18 Sep 20
4
SOLIGENIX / Diane L. Parks ownership change
19 Jun 20

Patents

APP
Utility
Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines
2 Dec 20
Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovirus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use.
APP
Utility
Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis
14 Oct 20
Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides.
APP
Utility
Topically Active Steroids for Use in Radiation and Chemotherapeutics Injury
20 May 20
Methods of delivering corticosteroids or metabolites thereof for treating and preventing tissue damage resulting from acute radiation injury in the gastrointestinal tract with locally effective therapeutic agents.
GRANT
Utility
Systems and methods for producing synthetic hypericin
6 Jan 20
Improved systems and methods for producing synthetic hypericin at high volume and high purity.

Reddit threads

View all